NEW YORK, December 8 (newratings.com) - Merck  amp; Co (MRK.NYS) has guided to lower-than-expected 2005 earnings due to the withdrawal of its blockbuster arthritis drug, Vioxx, and increased generic competition for its cholesterol drug, Zocor.